Scienza e Tecnologia
Global Natural Killer Cell Therapies Competitive Landscape, Technology, and Pipeline Analysis | DelveInsight
The report proffers a separate section for Natural Killer Augmenters including Natural Killer Cell Activators and Natural Killer Enhancers.
DelveInsight's NK Cell Therapies Market Landscape report covers and functional in the domain.
Some of the key takeaways from the NK Cell Therapies Competitive landscape, Technology, and Pipeline Analysis report:
Get in touch for deep and rich insights into Natural Killer Cell Therapies Competitive landscape, Technology, and Pipeline Analysis
Natural Killer (NK) Cells are recognized for their ability to kill cancerous cells. These are lymphocytes hailing from the same family as that of T and B cells, however, NK cells are classified as group I Innate Lymphocytes (ILCs) and respond quickly to a wide variety of conditions including cancer.
Natural Killer Cell Therapies in the Pipeline
NantKwest is developing an off-the-shelf natural killer cell-based therapeutic in combination with N-803 and ImmunityBio's IL-15 superagonist for the treatment of advanced refractory metastatic merkel cell carcinoma. The therapy leverages the company's hANK Cell Platform.
The drug is in of clinical development. A study titled " ". (NCT03853317) is currently with an estimated enrollment of 43 participants, and is expected to be completed in March 2022 .
Clinical Trials Description of NK Cell Therapies
Natural Killer Cell Therapies Market Landscape Upcoming Trends
Affimed, Altor Bioscience Corporation, AvidBiotic Corporation, Bristol-Myers Squibb, Celgene, CytoVac, Dynavax, Five Prime Therapeutics, Fortress Biotech, GamidaCell, Glycostem Therapeutics, iCell Gene Therapeutics, Innate Pharma, Multimmune GmbH, NantKwest, Nohla Therapeutics, PersonGen BioTherapeutics (Suzhou), Sorrento Therapeutics, Surface Oncology, ZIOPHARM Oncology, and others.
NK Cells Therapeutic Assessment
Natural Killer Cell Therapies Competitive Landscape
NK Cell Therapies Pipeline Analysis
Natural Killer Cell Therapies Pipeline Landscape and Emerging Trends
Natural Killer T-Cell Lymphoma Market
DelveInsight's " " report.
Car-T Cell Therapy for Acute Lymphoblastic Leukemia Market
DelveInsight's " " report.
Car-T Cell Therapy for Multiple Myeloma Market
DelveInsight's ' ' report.
Car-T Cell Therapy for Non-Hodgkins Lymphoma Market
DelveInsight's ' ' report.
Adult T Cell Leukemia Lymphoma Market
DelveInsight's " " report.
Chimeric Antigen Receptor Car-T Cell Immunotherapy Competitive Landscape Pipeline and Market Analysis
" ", report.
Advanced Renal Cell Carcinoma Market
DelveInsight's " " report.
Anaplastic Lymphoma Kinase Non-Small Cell Lung Cancer Market
DelveInsight's ' ' report.
Angioimmunoblastic T Cell Lymphoma Market
DelveInsight's " " report.
B Cell Chronic Lymphocytic Leukemia Market
DelveInsight's " " report.
DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve .
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg